Efficacy of combination therapy with ezetimibe and statins versus a double dose of statin monotherapy in participants with hypercholesterolemia: a meta-analysis of literature
Published 2020 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Efficacy of combination therapy with ezetimibe and statins versus a double dose of statin monotherapy in participants with hypercholesterolemia: a meta-analysis of literature
Authors
Keywords
-
Journal
Lipids in Health and Disease
Volume 19, Issue 1, Pages -
Publisher
Springer Science and Business Media LLC
Online
2020-01-04
DOI
10.1186/s12944-019-1182-5
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- A Phase III, Multicenter, Randomized, Double-blind, Active Comparator Clinical Trial to Compare the Efficacy and Safety of Combination Therapy With Ezetimibe and Rosuvastatin Versus Rosuvastatin Monotherapy in Patients With Hypercholesterolemia: I-ROSETTE (Ildong Rosuvastatin & Ezetimibe for Hypercholesterolemia) Randomized Controlled Trial
- (2018) Soon Jun Hong et al. CLINICAL THERAPEUTICS
- A randomized, controlled comparison of different intensive lipid-lowering therapies in Chinese patients with non-ST-elevation acute coronary syndrome (NSTE-ACS): Ezetimibe and rosuvastatin versus high-dose rosuvastatin
- (2017) Dan Ran et al. INTERNATIONAL JOURNAL OF CARDIOLOGY
- Krótkoterminowy wpływ terapii atorwastatyną i ezetimibem w porównaniu z monoterapią atorwastatyną na stan kliniczny chorych z ostrym zespołem wieńcowym w zależności od płci
- (2017) Lasha Japaridze et al. Kardiologia Polska
- Effect of ezetimibe add-on therapy over 52 weeks extension analysis of prospective randomized trial (RESEARCH study) in type 2 diabetes subjects
- (2017) Kentaro Sakamoto et al. Lipids in Health and Disease
- Efficacy and safety of adding alirocumab to rosuvastatin versus adding ezetimibe or doubling the rosuvastatin dose in high cardiovascular-risk patients: The ODYSSEY OPTIONS II randomized trial
- (2016) Michel Farnier et al. ATHEROSCLEROSIS
- Lipid lowering efficacy and safety of Ezetimibe combined with rosuvastatin compared with titrating rosuvastatin monotherapy in HIV-positive patients
- (2015) Ramesh Saeedi et al. Lipids in Health and Disease
- Effect of Ezetimibe on LDL-C Lowering and Atherogenic Lipoprotein Profiles in Type 2 Diabetic Patients Poorly Controlled by Statins
- (2015) Kentaro Sakamoto et al. PLoS One
- Effect of Switching From Statin Monotherapy to Ezetimibe/Simvastatin Combination Therapy Compared With Other Intensified Lipid‐Lowering Strategies on Lipoprotein Subclasses in Diabetic Patients With Symptomatic Cardiovascular Disease
- (2015) Ngoc‐Anh Le et al. Journal of the American Heart Association
- Achievement of 2011 European low-density lipoprotein cholesterol (LDL-C) goals of either
- (2013) Björn W. Karlson et al. ATHEROSCLEROSIS
- Differences in Action of Atorvastatin and Ezetimibe in Lowering Low-Density Lipoprotein Cholesterol and Effect on Endothelial Function
- (2013) Yuya Matsue et al. CIRCULATION JOURNAL
- Long-term effects of ezetimibe-plus-statin therapy on low-density lipoprotein cholesterol levels as compared with double-dose statin therapy in patients with coronary artery disease
- (2012) Kozo Okada et al. ATHEROSCLEROSIS
- Synergistic effect of simvastatin and ezetimibe on lipid and pro-inflammatory profiles in pre-diabetic subjects
- (2012) Ana-Lucia A Kater et al. Diabetology & Metabolic Syndrome
- Statin dose in Asians: is pharmacogenetics relevant?
- (2011) Ping Wang PHARMACOGENOMICS
- Ezetimibe/simvastatin 10/20 mg versus simvastatin 40 mg in coronary heart disease patients
- (2010) Maurizio Averna et al. Journal of Clinical Lipidology
- Prediction of cardiovascular event risk reduction from lipid changes associated with high potency dyslipidemia therapy
- (2009) Scott L. Charland et al. CURRENT MEDICAL RESEARCH AND OPINION
- The Role of Ethnicity in Variability in Response to Drugs: Focus on Clinical Pharmacology Studies
- (2008) SU Yasuda et al. CLINICAL PHARMACOLOGY & THERAPEUTICS
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationPublish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn More